Ilyang Pharmaceutical Launches Two Types of 'Dapaize Extended-Release Tablets' for Diabetes Blood Sugar Control
Improved Blood Sugar Control for Adults with Type 2 Diabetes
On December 4, Ilyang Pharmaceutical announced the launch of two types of Dapaize Extended-Release Tablets, a combination diabetes treatment for type 2 diabetes patients that combines the SGLT-2 inhibitor dapagliflozin and metformin to help control blood sugar levels.
Two types of diabetes treatment drug 'Dapaize Extended-Release Tablets'. Ilyang Pharmaceutical
View original imageThe main ingredient in Dapaize Extended-Release Tablets, dapagliflozin, is an SGLT-2 inhibitor that directly lowers blood sugar by inhibiting glucose reabsorption in the kidneys. Metformin is one of the most widely used ingredients for adequate glycemic control in patients with type 2 diabetes.
The two types released are 'dapagliflozin anhydrous lactose mixture (15.27 mg) + metformin hydrochloride (500 mg)' and 'dapagliflozin anhydrous lactose mixture (15.27 mg) + metformin hydrochloride (1000 mg)'. Typically, patients take one tablet once daily with dinner.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A representative from Ilyang Pharmaceutical stated, "With the addition of Dapaize Extended-Release Tablets to our portfolio, following the combination drug Januga Tablets (sitagliptin and dapagliflozin) and Januarin Duo Tablets available in three dosages, we are expanding our range of diabetes treatments. We aim to increase our presence and sales in the diabetes market by offering a variety of treatment options."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.